Stalevo
Stalevo
- In our pharmacy, you can buy Stalevo without a prescription, with delivery in 5–14 days throughout Canada (English). Discreet and anonymous packaging and shipment are available.
- Stalevo is used to treat Parkinson’s disease in adults experiencing motor fluctuations (“wearing off”) despite standard levodopa/DDCI therapy. It combines levodopa (a dopamine precursor), carbidopa (a peripheral dopa-decarboxylase inhibitor that reduces peripheral conversion of levodopa) and entacapone (a COMT inhibitor that prolongs levodopa’s plasma half-life), thereby increasing central dopaminergic activity.
- Usual dosing is matched to the patient’s current levodopa/DDCI regimen; commonly 1 tablet per dose taken 3–7 times daily and titrated to symptom control. Available tablet strengths (all contain 200 mg entacapone) include: Stalevo 50 (50 mg levodopa / 12.5 mg carbidopa), 75 (75/18.75), 100 (100/25), 125 (125/31.25), 150 (150/37.5) and 200 (200/50). Do not exceed 200 mg levodopa per dose or about 2,000 mg levodopa/day unless directed by a specialist.
- Form of administration: oral film‑coated tablets taken by mouth.
- Onset time: effects typically begin within about 20–60 minutes after an oral dose, depending on gastric emptying and individual response.
- Duration of action: symptom benefit generally lasts about 3–6 hours after a dose; the entacapone component tends to prolong levodopa effect and reduce “off” time, but duration varies between individuals.
- Alcohol warning: avoid excessive alcohol while taking Stalevo—alcohol can worsen dizziness, orthostatic hypotension, sedation and other adverse effects; consult your prescriber or pharmacist about modest alcohol use.
- The most common side effect is nausea. Other frequent effects include dyskinesia (involuntary movements), dizziness/orthostatic hypotension, diarrhoea, insomnia and brownish urine discoloration.
- Would you like to try “stalevo” without a prescription?
Basic Stalevo Information
- INN (International Nonproprietary Name): Levodopa, Carbidopa, Entacapone
- Brand Names Available In Canada (English): Stalevo, marketed by Novartis/Orion as film-coated tablets (brown, oval), Rx-only.
- ATC Code: N04BA03
- Forms & Dosages: Stalevo film-coated tablets containing 200 mg entacapone with levodopa/carbidopa in the following strengths — 50 (12.5 mg carbidopa + 50 mg levodopa), 75 (18.75 mg carbidopa + 75 mg levodopa), 100 (25 mg carbidopa + 100 mg levodopa), 125 (31.25 mg carbidopa + 125 mg levodopa), 150 (37.5 mg carbidopa + 150 mg levodopa), 200 (50 mg carbidopa + 200 mg levodopa).
- Manufacturers In Canada (English): Novartis/Orion (national subsidiaries handle distribution and labelling).
- Registration Status In Canada (English): Authorized for prescription use in Canada and marketed by Novartis/Orion.
- OTC / Rx Classification: Prescription Only Medicine (Rx).
Latest Research Highlights
Do clinicians still consider adding entacapone useful for patients with motor "wearing-off"?
Recent systematic reviews and registry analyses through 2025 continue to support a role for adding entacapone to levodopa/DDCI in adults with Parkinson’s experiencing motor fluctuations.
Canadian movement-disorder centre audits and provincial cohort reports from 2022–2025 emphasise sustained reductions in daily "off" time when fixed-dose levodopa/carbidopa/entacapone tablets are used instead of separate tablets.
Real-world Canadian reports also note lower pill burden and improved adherence after switching from levodopa/DDCI plus separate entacapone to fixed-dose triple combinations.
International RCT follow-ups and EMA/FDA post-marketing surveillance through 2025 confirm known safety signals such as dyskinesia, orthostatic hypotension, and brown urine, while documenting better adherence in older adults when regimens are simplified.
| Study Type | Population | Primary Outcome | Key Result |
|---|---|---|---|
| Systematic Review (2022–2025) | Adults with Parkinson’s and wearing-off | Change in daily off-time | Consistent reduction in off-time with entacapone addition |
| Provincial Cohort Audit | Real-world routine care patients (Canada) | Adherence and pill burden | Improved adherence and fewer tablets per day after fixed-dose switch |
| EMA/FDA Post-Marketing Analysis | International surveillance | Safety signals | Reinforced dyskinesia and orthostatic hypotension; urine discoloration noted |
Canadian clinicians should interpret these findings alongside provincially variable access and bilingual information needs.
Rural patients often face longer waits for movement-disorder clinics and may benefit from simplified regimens that ease home management and reduce caregiver burden.
Data Highlights
- Stalevo INN: levodopa, carbidopa, entacapone.
- Approvals: Health Canada (marketed), FDA (NDA #021485, 2003), EMA (2005).
- Real-world benefits: reduced off-time and lower pill burden reported in Canadian audits.
Clinical Effectiveness In Canada
How well does the fixed-dose triple compare to separate agents in everyday Canadian practice?
Canadian product monographs and provincial case series between 2022 and 2025 report comparable effectiveness for fixed-dose levodopa/carbidopa/entacapone versus separate levodopa/DDCI plus entacapone at reducing "off" time.
Real-world dispensing and adherence data show gains where pill counts and dosing frequency drop after conversion to a single-tablet option.
| Province | Reported Outcome | Adherence Metric |
|---|---|---|
| Ontario | Reduced daily off-time in clinic audits | Higher proportion of patients with ≥80% adherence |
| British Columbia | Fewer daily doses needed after switch | Improved refill continuity |
| Quebec | Sustained motor benefit reported | Better reported satisfaction and adherence |
Stalevo is approved for prescription use in Canada and the product monograph and Health Canada Drug Product Database list formulation details and DIN information.
Provincial formularies such as Ontario Drug Benefit, BC PharmaCare, and RAMQ may list Stalevo with specific coverage criteria and prior-therapy requirements.
- Step 1: Verify the product DIN and strength on the Health Canada DPDB.
- Step 2: Document prior levodopa/DDCI response in chart notes for prior-authorization requests.
- Step 3: Submit specialist recommendation when required by the provincial formulary.
- Step 4: Use pharmacist follow-up to document adherence and ongoing benefit.
Pharmacist-led follow-up and bilingual counselling improve outcomes and support coverage requests.
Indications And Expanded Uses
When is Stalevo indicated, and are there off-label uses clinicians consider?
The approved indication remains treatment of Parkinson’s disease in adults with motor fluctuations ("wearing off") despite standard levodopa/DDCI therapy.
Observational practice data show some clinicians using fixed‑dose triple tablets to simplify dosing for patients with erratic absorption or adherence challenges, but evidence for early-stage augmentation or other off‑label uses is limited.
- Approved Indication — Treatment of Parkinson’s disease in adults experiencing motor fluctuations ('wearing off') despite standard levodopa/DDCI therapy.
- Off-Label Uses — Dose optimisation for adherence issues (observational evidence only).
In Canadian practice, specialists commonly initiate Stalevo, while family physicians and community pharmacists manage ongoing therapy and monitoring.
Off‑label prescribing requires informed consent, documentation, and is usually not eligible for routine provincial coverage.
Composition And Brand Landscape
What exactly is inside each tablet and how is Stalevo supplied?
The INN is levodopa, carbidopa, entacapone, and all marketed Stalevo strengths contain 200 mg entacapone plus varying levodopa/carbidopa ratios.
| Strength Code | Carbidopa (mg) | Levodopa (mg) | Entacapone (mg) |
|---|---|---|---|
| Stalevo 50 | 12.5 | 50 | 200 |
| Stalevo 75 | 18.75 | 75 | 200 |
| Stalevo 100 | 25 | 100 | 200 |
| Stalevo 125 | 31.25 | 125 | 200 |
| Stalevo 150 | 37.5 | 150 | 200 |
| Stalevo 200 | 50 | 200 | 200 |
In Canada Stalevo is the principal brand marketed by Novartis/Orion and packaging uses English and French labelling as standard.
Generic fixed-dose triple alternatives may be limited in Canada and pharmacists should check the Health Canada DPDB for current DIN and generic listings before substitution.
Contraindications And Special Precautions
Who must not take Stalevo, and who needs closer monitoring?
Absolute contraindications include known hypersensitivity to any component, narrow-angle glaucoma, severe liver disease, and pheochromocytoma because of hypertensive crisis risk.
Relative concerns include severe cardiovascular disease, severe renal impairment, history of psychosis, and concomitant non-selective MAOI use.
- Absolute Contraindications: Hypersensitivity to components; narrow-angle glaucoma; severe liver disease; pheochromocytoma.
- Relative Contraindications: Severe cardiovascular disease; severe renal impairment; history of psychosis; non-selective MAOI coadministration.
Elderly patients often require lower starting doses and close monitoring for orthostatic hypotension and dyskinesia.
Culturally safe counselling and coordination with primary care and community pharmacists is important for Indigenous and remote communities that face barriers to specialist follow-up.
Dosage Guidelines
How should Stalevo be started and titrated in Canada?
Initiation is matched to the patient’s existing levodopa/DDCI dose and titration uses the closest Stalevo tablet to maintain levodopa exposure while reducing pill burden.
Maintenance dosing commonly involves one tablet per dose taken three to seven times daily as needed for symptom control.
| Common Levodopa/DDCI Regimen | Approximate Stalevo Conversion |
|---|---|
| Sinemet 100/25 single dose | Consider Stalevo 100 (25/100/200) to match exposure |
| Sinemet 50/12.5 single dose | Consider Stalevo 50 (12.5/50/200) |
| Levodopa higher dose needs | Match to nearest available Stalevo strength up to 200 mg levodopa per dose |
Maximum recommended limit is not to exceed 200 mg levodopa per dose or 2,000 mg/day total per product summaries.
Children under 18 years: not indicated.
Use caution and monitor renal impairment, and avoid or reduce dose in hepatic impairment because entacapone exposure increases.
Pharmacist-led dose reconciliation reduces conversion errors when switching to fixed-dose tablets.
Interactions Overview
Which medicines and food interactions matter most for people taking Stalevo?
Major interactions reflect levodopa and entacapone pharmacology and are highlighted in Canadian monographs and up-to-date interaction resources.
- Non-Selective MAO Inhibitors — contraindicated due to hypertensive crisis risk.
- Dopaminergic/Psychiatric Agents — additive psychosis risk may occur when combined with other dopaminergic drugs or certain antipsychotics.
- Antihypertensives — orthostatic hypotension risk can be increased.
- High-Protein Meals — may delay levodopa absorption and reduce efficacy; counsel on protein-spacing.
- Hepatic Metabolism Modifiers — drugs affecting liver enzymes can alter entacapone exposure and warrant monitoring.
Patients should be counselled about benign brown urine discolouration to avoid alarm.
| Top Interacting Drug Classes In Canadian Seniors | Clinical Concern |
|---|---|
| Antidepressants (especially MAOIs) | Hypertensive crisis or serotonin/psychiatric interactions |
| Antihypertensives | Exacerbation of orthostatic hypotension |
| Antipsychotics | Reduced efficacy or increased psychosis risk when combined |
| Protein-rich diets/levodopa timing | Reduced absorption and variable motor response |
Cultural Perceptions And Patient Habits
What do Canadian patients say about Stalevo and simplified regimens?
Patient forum analyses through 2024–25 show that Canadians value simplified regimens, clear bilingual labelling, and predictable symptom control.
Common concerns include cost, dyskinesia as a side effect, and access challenges in rural and Indigenous communities.
| Setting | Access Pattern | Common Barrier |
|---|---|---|
| Urban | Closer access to neurology clinics and specialty pharmacies | Cost and formulary restrictions |
| Rural | Care mainly through family physicians and community pharmacists | Longer wait times and limited specialist follow-up |
- Recommend written bilingual instructions and caregiver training.
- Provide culturally safe counselling and coordinate with primary care providers for remote patients.
Francophone patients in Quebec often request French product monographs and counselling materials.
Availability And Pricing Patterns
How accessible is Stalevo in Canadian pharmacies and how do prices compare?
Market surveys from 2022–2025 show price variability across Canada and differences compared with US retail pricing.
Public formulary coverage can reduce out-of-pocket costs for eligible patients while private plan rules remain variable.
| Example Market | Retail Price Pattern | Provincial Reimbursement Notes |
|---|---|---|
| Canada (Retail) | Variable by chain and region; check local pharmacy | ODB, BC PharmaCare, RAMQ may require prior therapy documentation |
| United States (Retail) | Sometimes lower list prices; varies with insurance | Cross-border importation rules complicate access |
Stalevo is prescription-only and supplied in blister packs with EN/FR labelling in Canada.
Major Canadian chains that commonly stock Stalevo include Shoppers Drug Mart, Rexall, London Drugs, and Jean Coutu, but stock policies vary between community and hospital pharmacies.
In our online pharmacy, stalevo is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.
- Step 1: Check the Health Canada DPDB for the DIN and marketed pack sizes.
- Step 2: Confirm provincial formulary criteria before prescribing if cost coverage is needed.
- Step 3: Appeal denials with documented prior levodopa response and specialist notes.
Comparable Medicines And Preferences
What are the practical alternatives and how do they compare?
Comparative evidence supports triplet fixed-dose formulations as a way to streamline therapy compared with separate levodopa/DDCI plus entacapone.
| Medicine | Pros | Cons |
|---|---|---|
| Stalevo | Single tablet contains entacapone; reduces pill burden | Less flexibility for individual component titration |
| Sinemet + Comtan | Flexible dosing for individual components | Higher pill count and possible adherence issues |
| Madopar | Alternative levodopa formulation (not commonly used in Canada) | Different DDCI (benserazide) and less local familiarity |
Decision factors include prior levodopa response, dyskinesia profile, coverage, pill burden, and patient preference.
Pharmacists should check DIN-based alternatives and counsel patients on conversion and monitoring.
Frequently Asked Questions
What Is Stalevo For?
Stalevo is a prescription treatment for Parkinson’s disease in adults with motor "wearing off" despite levodopa/DDCI therapy and contains levodopa, carbidopa, and entacapone.
Will My Provincial Plan Cover It?
Coverage varies by province; Ontario Drug Benefit, BC PharmaCare and RAMQ may require prior therapy documentation or a specialist recommendation — check with the pharmacist and provincial formulary.
Can I Take It With My Antidepressant?
Certain antidepressants interact; non-selective MAOIs are contraindicated and other antidepressants require review — always provide a full medication list to the prescriber and pharmacist.
What Side Effects Should I Watch For?
Common side effects include nausea, dyskinesia, dizziness/orthostatic hypotension, insomnia, and brown urine discolouration; seek urgent care for severe neuropsychiatric changes or arrhythmia.
Printable Checklist For Patients
- Know your tablet strength and dosing schedule.
- Watch for new or worsening involuntary movements.
- Stand up slowly to reduce dizziness and orthostatic symptoms.
- Keep a list of all medicines and share it at each appointment.
- Call your pharmacist or prescriber for new or concerning symptoms.
Guidelines For Proper Use
How should pharmacists counsel patients starting Stalevo in Canada?
Match initiation to the prior levodopa/DDCI dose and titrate to the closest available Stalevo tablet while monitoring motor response and tolerability.
- Confirm DIN and exact tablet strength before dispensing.
- Counsel in the patient’s preferred language and provide written EN/FR instructions.
- Advise on protein spacing to optimise levodopa absorption.
- Warn about benign urine discolouration and orthostatic precautions.
Missed Dose: Take as soon as possible but do not double the next dose.
Overdose: Seek emergency care — symptoms may include severe dyskinesia, confusion, or arrhythmia.
Storage: Store below 30°C and protect from moisture and light; transport in original packaging.
Coordination Of Care
- Document therapy rationale for provincial reimbursement requests.
- Schedule follow-up for motor response and dyskinesia assessment within 4–8 weeks of conversion.
- Liaise with movement-disorder specialists for dose adjustments in renal or hepatic impairment.
Delivery Across Canada (English)
| City | Region | Delivery Time |
|---|---|---|
| Toronto | Ontario | 5-7 days |
| Vancouver | British Columbia | 5-7 days |
| Montreal | Quebec | 5-7 days |
| Calgary | Alberta | 5-7 days |
| Edmonton | Alberta | 5-7 days |
| Ottawa | Ontario | 5-7 days |
| Winnipeg | Manitoba | 5-7 days |
| Halifax | Nova Scotia | 5-9 days |
| Victoria | British Columbia | 5-9 days |
| Saskatoon | Saskatchewan | 5-9 days |
| Regina | Saskatchewan | 5-9 days |
| St. John’s | Newfoundland and Labrador | 5-9 days |
| Charlottetown | Prince Edward Island | 5-9 days |
| Whitehorse | Yukon | 5-9 days |
Final Practical Notes
When switching a patient to a fixed-dose triple tablet, document prior levodopa response and expected benefits to support funding requests.
Pharmacists should reconfirm the DIN and pack size, provide clear bilingual counselling, and schedule follow-up to assess motor benefit and adverse effects.
Keep lines of communication open with specialists for dose adjustments and with patients and caregivers to support adherence.
For clinical details and product-specific warnings consult the Health Canada Drug Product Database and the Stalevo product monograph.